Wednesday 18 February 2026
Lundbeck prepares Phase 3 plans for PACAP antibody in migraine prevention
If you live with migraine, you’ll know how tough it can be when prevention options don’t help enough — especially if your migraines feel more intense, more frequent, or harder to settle. This week, there’s a hopeful research update: scientists may be getting closer to a brand-new prevention pathway.
What’s the news?
Denmark-based Lundbeck says its investigational migraine-prevention medicine bocunebart (also known as Lu AG09222) met its main goal in the Phase 2b PROCEED trial, reducing monthly migraine days compared with placebo in people who previously didn’t respond well to other preventives. The company is now preparing discussions with regulators about a Phase 3 programme.
Why this feels different
Many current preventives focus on well-known migraine pathways like CGRP (and in some cases serotonin-related targets). Bocunebart focuses on PACAP — a neuropeptide increasingly linked to migraine biology. If PACAP-targeting therapies succeed in later trials, they could add another option to the prevention “toolkit,” particularly for people who haven’t had the results they hoped for with existing approaches.
What the trial included (in plain English)
- About 430 people took part.
- Participants had experienced 1 to 4 previous preventive treatment failures over the past 10 years.
- They were followed for 12 weeks.
- The IV formulation showed a dose-response relationship (higher doses helped more) and was described as generally well tolerated, with no new safety signals reported.
Notably, Lundbeck previously paused work on a subcutaneous injection version and switched focus to an IV formulation — and it’s the IV results that are now driving Phase 3 planning.
A quick reality check (and some hope)
Migraine research is complex, and not every promising early result becomes a widely available treatment. But this update is an encouraging sign that researchers are continuing to push forward — including for people who have already tried multiple preventive options.
While science moves forward, small daily supports still matter.
Many people find that steadier sleep and wake times, regular meals, hydration, and simple trigger-pattern tracking can make migraine feel more predictable — even alongside medical care.
Available today
Support for people who experience more acute, disruptive migraines
New prescription options are still in research, but if your migraines feel more acute and you want to strengthen your day-to-day routine with gentle nutritional support, these are two of our most popular choices. They’re designed to fit alongside a migraine-aware lifestyle — think consistency, simplicity, and support you can build into daily life.
MigraSoothe Triple Pack
A great-value bundle for those who want consistent, 360 degree ongoing support with NHS backed supplements — ideal if you’re building a steadier routine and prefer to stock up. (NICE CG150)
Shop Triple PackMigraSoothe Pro
A premium option for people who want a focused, high-strength daily approach as part of a consistent routine and a mood booster — especially if migraines regularly disrupt plans, work, or sleep.
Shop MigraSoothe ProIf you’re pregnant, breastfeeding, taking medication, or under medical supervision, please speak with a healthcare professional before starting supplements.
Important: This is health news and not medical advice. Always speak to a qualified healthcare professional about diagnosis, treatment, and whether any approach is suitable for you.
Sources: Pharmaphorum (13 Feb 2026) and Lundbeck’s PROCEED trial top-line announcement (12 Feb 2026).